|
American Diabetes Association. Standards
of Medical Care for Patients With Diabetes Mellitus. Diabetes
Care 2003;26:S33-S50.
Brenner BM, Cooper ME, Zeeuw DD, et
al. The losartan renal protection study--rationale, study
design and baseline characteristics of RENAAL (Reduction
of Endpoints in NIDDM with the Angiotensin II Antagonist
Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-335.
Chan JC, Hawkins BR, and Cockram CS. A
Chinese family with non-insulin-dependent diabetes of early
onset and severe diabetic complications. Diabet Med 1990;7:211-214.
Diabetes Division Hong Kong Society
for Endocrinology Metabolism and Reproduction. A statement
for health care professionals on type 2 diabetes mellitus
in Hong Kong. Hong Kong Med J 2000;6:105-107.
Hattersley AT and Tattersall RB.
Maturity-onset diabetes of the young. In: Textbook of Diabetes.
Second ed. Pickup, J. C. and Williams, G. (ed). Oxford, UK:
Blackwell Science Ltd, 22.1-22.10.
Heart Outcomes Prevention Evaluation
Study Investigators. Effects of ramipril on cardiovascular
and microvascular outcomes
in people with diabetes mellitus: results of the HOPE study
and MICRO-HOPE substudy. Lancet 2000;355:253-259.
Leung GM and Lam KS. Diabetic complications
and their implications on health care in Asia. Hong Kong
Med J 2000;6:61-68.
Lewis EJ, Hunsicker LG, Bain RP, et al.
The effect of angiotensin-converting-enzyme inhibition on
diabetic nephropathy. The Collaborative Study Group. N Engl
J Med 1993;329:1456-1462.
Ng MC, Li JK, So WY, et al. Nature or
nurture: an insightful illustration from a Chinese family
with hepatocyte nuclear factor-1 alpha diabetes (MODY3).
Diabetologia 2000;43:816-818.
Velho G and Robert J-J. Maturity-onset
Diabetes of the Young (MODY): Genetic and Clinical Characteristics.
Horm Res 2002;57:29-33.
|
